Registration Programme Overview Exhibition Virtual Exhibition Satellite Programme Hotel Information VISA Letter Application

 

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Allogeneic corneal small incision intrastromal lenticule inlays for hyperopia (3 years)

Poster Details


First Author: J.Zhang CHINA

Co Author(s): Y. Zhou                    

Abstract Details

Purpose:

To evaluate the safety, effectiveness and predictability of allogeneic corneal small incision intrastromal lenticule inlays to correct hyperopia.

Setting:

Ophthalmic Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing, China. Mingshiguang Eye Hospital, Beijing, China.

Methods:

It was a prospective case-control study. Thirty-three hyperopic patients (58 eyes) were performed with allogeneic corneal small incision intrastromal lenticule inlays. All the cases were followed up for 3 years. Uncorrected and best corrected visual acuity and refraction were compared between before and after operation. Corneal topography and optical coherence topography were examined to reflect corneal topogeaphy. Ocular response analyzer was used to evaluate the shifts of corneal hysteresis.

Results:

No intraoperative and postoperative complications were found. The 55 corneas (94.83%) remained clear without decentered lenticule over the 3-years postoperatively. Only 3 lenticules (5.17%) of 2 patients needed to change epinephelos lenticules to new ones. Uncorrected distance (UCDVA) and near visual acuity (UCNVA) improved obviously after surgery. Mild overcorrection was the state early after operation, and the diopter was stable from 1 month to 3 years after surgery. The average residual spherical equivalent was (-0.39±1.27)D, which improved obviously from (+6.23±2.54)D before surgery. The corneal biomechanics didn’t change before and after surgery.

Conclusions:

Allogeneic corneal len inlays can be used to correct hyperopic eye with good safety, effectiveness and predictability. It provides a new choice for hyperopic patients.

Financial Disclosure:

None

Back to Poster listing